Quarterly ResultMay 1, 2026, 04:15 PM
IRADIMED Q1 Revenue +13% to $22.0M; Diluted EPS $0.45
AI Summary
IRADIMED reported strong financial results for the first quarter of 2026, with revenue increasing 13% to $22.0 million and net income rising 24.1% to $5.8 million. Diluted earnings per share reached $0.45, up from $0.37 in the prior year. The company also saw a significant increase in cash and cash equivalents, reaching $56.374 million, and its Board declared a quarterly cash dividend of $0.20 per share.
Key Highlights
- Q1 2026 revenue increased 13% to $22.0 million from $19.5 million in Q1 2025.
- Net income rose 24.1% to $5.8 million, up from $4.7 million in the prior year.
- Diluted EPS was $0.45, an increase from $0.37 in the same period last year.
- Cash and cash equivalents grew to $56.374 million as of March 31, 2026.
- Net cash provided by operating activities was $8.290 million, up from $4.292 million.
- US revenue increased 13% to $18.0 million; International revenue rose 11.1% to $3.954 million.
- IV Infusion Pump Systems revenue grew 27.7% to $7.664 million.
- Board declared a quarterly cash dividend of $0.20 per share payable May 29, 2026.
Price Impact
More from IRMD